BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/2/2024 9:08:46 AM | Browse: 50 | Download: 144
 |
Received |
|
2023-10-30 08:58 |
|
Peer-Review Started |
|
2023-10-30 08:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-11-08 06:06 |
|
Revised |
|
2023-11-23 20:16 |
|
Second Decision |
|
2023-12-18 02:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-12-18 06:34 |
|
Articles in Press |
|
2023-12-18 06:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-12-23 02:28 |
|
Publish the Manuscript Online |
|
2024-01-02 09:08 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen (CA) 125, CA199 analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Dong-Bing Zhou, Jun Cheng and Xiong-Hui Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xiong-Hui Zhang, N/A, Chief Doctor, Department of Gastroenterology, Xiantao First People's Hosepital Affiliated to Yangtze University, No. 29 Central Mianzhou Avenue, Xiantao 433000, Hubei Province, China. xionghui0708@sina.com |
| Key Words |
Metastatic colorectal cancer; Bevacizumab; Capecitabine; XELOX; Tumor markers |
| Core Tip |
Colorectal cancer has a high incidence in the population. The clinical treatment of colorectal cancer is basically XELOX intervention. Prognostic determination of serum tumor markers is a common index to evaluate the efficacy of cancer drugs. Therefore, we studied the therapeutic effect and serum tumor markers of patients with colorectal cancer under different treatments. The results showed that the therapeutic effect of XELOX + capecitabine (CAP) + bevacizumab was better than that of XELOX + CAP, which showed that the serum carcinoembryonic antigen, carbohydrate antigen (CA) 199 and CA125 levels were lower and the median survival time was longer, and all of them were statistically significant. |
| Publish Date |
2024-01-02 09:08 |
| Citation |
Zhou DB, Cheng J, Zhang XH. Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen (CA) 125, CA199 analysis. World J Clin Cases 2024; 12(1): 15-23 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i1/15.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i1.15 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
